Nature Immunology's AI Policy: What Immunology Authors Need to Know About Disclosure
Nature Immunology follows Springer Nature's AI policy with Methods disclosure required, plus guidance on single-cell analysis pipelines, immune repertoire data, and clinical immunology considerations.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Nature Immunology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 27.6 puts Nature Immunology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~5-8% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Nature Immunology takes ~5 day. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: Immunology papers are getting more computational every year. Between single-cell transcriptomics, spatial proteomics, systems immunology modeling, and the growing role of AI in predicting immune responses, the average Nature Immunology manuscript now contains significantly more bioinformatics than it did a decade ago. The journal's AI policy addresses one specific slice of this computational landscape: AI tools used for writing, not for research. But for immunology authors juggling both, knowing where to draw the line matters.
Nature Immunology AI Policy at a Glance
- AI authorship: Prohibited. AI tools cannot be listed as authors and cannot take accountability for the work.
- AI disclosure: Required. Disclose use of AI tools (e.g., ChatGPT, Claude, Gemini) in the Methods section.
- AI-generated images: Prohibited. AI-created figures, illustrations, or visualizations are not permitted in the manuscript.
- Copy editing: Copy editing for grammar and language is exempt from disclosure.
The policy
Nature Immunology follows the Springer Nature AI policy. Same rules as Nature, Nature Medicine, Nature Genetics, and the rest of the 3,000+ journal portfolio:
- AI can't be an author. No listing LLMs or generative AI tools as co-authors.
- AI use in manuscript preparation must be disclosed in Methods. Name the tool, describe how it was used, specify which sections.
- AI-generated images are banned. No generative AI figures, graphical abstracts, or illustrations.
- Copy editing exempt. Grammar and spelling tools don't need disclosure.
- Authors are fully responsible for all content.
There are no Nature Immunology-specific modifications. The journal's Instructions for Authors point to the centralized Springer Nature policy page.
Publisher-wide vs. journal-level implementation
The Springer Nature AI policy is set centrally, but how it plays out varies by journal because of the research community's characteristics:
Aspect | Springer Nature (general) | Nature Immunology (in practice) |
|---|---|---|
Policy text | Standard | Identical |
Computational content in papers | Varies | High and increasing |
scRNA-seq/CyTOF analysis | Some journals | Very common |
Clinical immunology content | Some journals | Significant subset |
Reviewer computational literacy | Varies | Generally high |
Community size | N/A | Small, interconnected |
The community size point matters for enforcement. Nature Immunology's authorship network is relatively concentrated, the same researchers appear as authors, reviewers, and editorial board members. If your paper has an AI disclosure issue and it becomes known, word travels fast.
Single-cell analysis pipelines
Single-cell immunology is where most AI-related questions arise. A typical Nature Immunology scRNA-seq paper involves:
- Quality control and filtering
- Normalization and batch correction
- Dimensionality reduction (PCA, UMAP)
- Clustering and cell type annotation
- Differential expression analysis
- Trajectory inference
- Gene regulatory network analysis
If you used Copilot or ChatGPT to help write code for any of these steps, that's AI-assisted manuscript preparation (specifically, code generation) requiring disclosure. The analysis tools themselves, Seurat, Scanpy, Harmony, scVI, aren't AI writing tools and don't need to be disclosed under the AI policy (they go in standard Methods as analysis software).
Disclosure example for an scRNA-seq paper:
"Single-cell RNA-seq analysis was performed using Seurat v5 (R) and Scanpy (Python) as described in Methods. GitHub Copilot (Microsoft) was used to assist with writing custom R scripts for the cell type annotation pipeline. All scripts were validated against manual annotation of a reference dataset. ChatGPT (GPT-4, OpenAI) was used to improve the language of the Discussion section. The authors take full responsibility for the published content."
Immune repertoire analysis
TCR and BCR repertoire sequencing generates massive datasets that require specialized computational tools. If AI helped with writing analysis code for clonotype identification, CDR3 analysis, or repertoire diversity calculations, disclose it.
But don't confuse the analysis tools with writing tools. immunarch, MiXCR, and TRUST4 are bioinformatics software described in Methods. ChatGPT helping you write a wrapper script around these tools is AI-assisted code generation requiring separate disclosure.
Clinical immunology and patient data
Nature Immunology publishes translational and clinical immunology research involving patient samples. The same data privacy concerns that apply at Nature Medicine apply here: don't input patient data, clinical records, or identifiable information into cloud-based AI tools.
For papers involving autoimmune disease cohorts, vaccine trial immunogenicity data, or transplant immunology with patient outcomes, keep AI tools away from clinical interpretation sections.
Writing the disclosure
For a systems immunology paper:
"During manuscript preparation, the authors used ChatGPT (GPT-4, OpenAI) to improve the clarity of the Results and Discussion sections. The computational modeling described in this study (immune response ODE model) was developed and parameterized by the authors without AI assistance. The authors take full responsibility for the published content."
For a paper with multi-omics integration:
"The authors used Claude (Claude 3.5, Anthropic) to edit the Introduction for language clarity. GitHub Copilot (Microsoft) assisted with writing Python scripts for integrating CyTOF and scRNA-seq datasets. All integration code was validated against published reference datasets (see Methods: Data Integration Validation). No patient-identifiable data was processed through any cloud-based AI tool."
For a basic immunology paper:
"During preparation of this manuscript, the authors used ChatGPT (GPT-4, OpenAI) to improve the readability of the Methods section. All content was reviewed by the senior author (K.Y.). The authors take full responsibility for the content of the published article."
What requires disclosure
Use case | Disclosure required? | Immunology notes |
|---|---|---|
Standard grammar tools | No | Exempt |
ChatGPT for language editing | Yes | Methods section |
AI for scRNA-seq code | Yes | Specify which pipeline steps |
Seurat/Scanpy usage | No (research tool) | Standard Methods description |
AI for flow cytometry analysis code | Yes | Confirm gating strategy was human-defined |
AI-generated immune cell diagrams | Prohibited | Use BioRender instead |
AI for TCR/BCR repertoire code | Yes | Confirm validation of repertoire calls |
AI for figure legends | Yes | Part of the manuscript |
AI for literature search on cytokines | Yes | Describe scope |
AI for grant-to-paper text adaptation | Yes | Generating new manuscript text |
The flow cytometry gating strategy point is important. Gating decisions in flow and CyTOF experiments are scientific judgments that should be made by trained immunologists. If AI influenced your gating strategy, this isn't just a disclosure issue, it's a scientific integrity question. The analysis code can be AI-assisted, but the gating logic should come from the investigators.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Consequences of non-disclosure
Standard Springer Nature enforcement:
- During review: Request to add disclosure; possible rejection if concealment appears deliberate
- After publication: Correction, expression of concern, or retraction depending on severity
Immunology community dynamics: Nature Immunology publishes approximately 150-200 research articles per year. The immunology community is small enough that most researchers in a given subfield know each other. A publication ethics issue at this journal has outsized reputational consequences compared to a megajournal.
If your paper involves collaboration between immunology labs and computational biology groups, which is increasingly common, make sure both sides contribute to the AI disclosure. The wet-lab PI may not know that the bioinformatics collaborator used Copilot for the analysis pipeline, and the bioinformatics lead may not know that the first author used ChatGPT to rewrite the Introduction.
Comparison with other immunology journals
Feature | Nature Immunology | Immunity | Journal of Experimental Medicine | Journal of Immunology | Frontiers in Immunology |
|---|---|---|---|---|---|
Publisher | Springer Nature | Cell Press (Elsevier) | Rockefeller UP | AAI (Oxford UP) | Frontiers |
AI authorship | Prohibited | Prohibited | Prohibited | Prohibited | Prohibited |
Disclosure location | Methods | STAR Methods | Methods | Methods | Methods |
AI image ban | Yes | Yes | Yes | Yes | Yes |
Copy editing exemption | Yes | Implicit | Yes | Yes | Yes |
Impact factor range | ~25-30 | ~25-30 | ~15 | ~4-5 | ~5-7 |
scRNA-seq papers | Very common | Very common | Common | Common | Common |
Immunity (Cell Press) uses STAR Methods format, so your AI disclosure goes in Method Details rather than a free-form Methods section. The Journal of Immunology (AAI) follows Oxford University Press guidelines. Frontiers in Immunology follows Frontiers' publisher-wide policy. The substantive requirements are similar across all five journals, the differences are in formatting and enforcement culture.
For authors choosing between Nature Immunology and Immunity: the AI policies are functionally equivalent. The disclosure format differs (Methods vs. STAR Methods), but the rules and consequences are the same.
Timeline and policy stability
Nature Immunology adopted Springer Nature's AI policy when it was formalized in early 2023. The core principles haven't changed since:
Date | Development |
|---|---|
January 2023 | Springer Nature publishes initial editorial stance on AI |
Early 2023 | Formal policy added to author guidelines across Nature Portfolio |
Mid 2023 | Image generation ban added explicitly |
2024 | Disclosure requirements refined; copy editing exemption clarified |
2025–2026 | Policy stable; enforcement integrated into submission workflow |
This stability matters for immunology researchers planning multi-year projects. If you're midway through a study that won't be submitted for another year, the current rules are very likely the rules you'll face at submission time. Science (AAAS) went through multiple policy revisions, initially banning all AI text, then switching to a disclosure model. Springer Nature's approach was always disclosure-based from the start, so Nature Immunology authors haven't had to deal with moving goalposts.
Practical advice for Nature Immunology submissions
For single-cell immunology papers:
- Keep a record of which analysis code was AI-assisted and which was written from scratch
- If your cell type annotations used any AI-based automatic annotation tools, describe these as analysis methods, not in the AI writing disclosure
- Validate all AI-generated code against published reference datasets before including in the paper
For vaccine and clinical immunology:
- Don't process participant immunological data through cloud AI tools
- Keep AI away from efficacy claims and clinical outcome descriptions
- If your paper includes immune correlates of protection, the interpretation should be entirely human-driven
For mechanistic immunology papers:
- AI can help with language, but descriptions of signaling pathways, knockout phenotypes, and molecular mechanisms should reflect what you observed, not what an LLM predicts based on training data
- Be careful with AI-edited Discussion sections, LLMs may insert claims about immune mechanisms that sound plausible but don't match your specific experimental system
Before submission checklist:
- [ ] AI disclosure in Methods with tool names, versions, use cases
- [ ] Research tools (Seurat, Scanpy, FlowJo) described in standard Methods
- [ ] Writing/code tools (ChatGPT, Copilot) in separate AI disclosure
- [ ] No patient/participant data processed through cloud AI
- [ ] No generative AI images or pathway diagrams
- [ ] All co-authors aware of AI disclosure
- [ ] AI-assisted code validated independently
A Nature Immunology submission readiness check can help verify your Nature Immunology submission meets editorial and disclosure standards.
What should you do about Nature Immunology's's AI policy?
Comply proactively if:
- You used any AI tool (ChatGPT, Grammarly, Copilot) during manuscript preparation
- The journal requires AI use disclosure in the methods or acknowledgments
- Your institution has its own AI use policy that may be stricter
Less concerned if:
- You used AI only for grammar/spell checking (most journals exempt this)
- The journal does not have a formal AI policy yet
- Your use was limited to literature search or reference management
Frequently asked questions
Yes, under Springer Nature's standard AI policy. Authors can use AI tools for language editing and preparation, with mandatory disclosure in the Methods section. AI can't be listed as an author, and AI-generated images are prohibited.
No. The policy is identical across all Nature Portfolio journals. Nature Immunology follows the same Springer Nature rules as Nature, Nature Medicine, Nature Genetics, and every other title in the portfolio.
If AI assisted with writing analysis code for scRNA-seq, CyTOF, or CITE-seq pipelines, disclose this in Methods and specify which analysis steps were AI-assisted. The bioinformatics tools themselves (Seurat, Scanpy, FlowJo) aren't covered by the AI disclosure policy. Keep research tools and writing tools clearly separated in your disclosure.
No, if you're using generative AI tools like DALL-E or Midjourney. Pathway diagrams created with BioRender, Illustrator, or similar design tools are fine. The ban is on generative AI-produced images, not on all computer-generated graphics.
Standard Springer Nature enforcement: correction for minor cases, expression of concern for unclear scope, retraction for serious cases. Nature Immunology's tight-knit research community means publication ethics issues circulate quickly among peers.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Nature Immunology Submission Guide
- How to Avoid Desk Rejection at Nature Immunology
- Is Nature Immunology a Good Journal? Fit Verdict
- Nature Immunology APC and Open Access: Current Nature Portfolio Pricing and What the Fee Buys
- Pre-Submission Review for Immunology Journals: What Nature Immunology and Immunity Reviewers Expect
- Rejected from Nature Immunology? The 7 Best Journals to Submit Next
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.